"Advancing Vaccine Development: A Global Investment Priority"

The COVID-19 pandemic has accelerated vaccine development, with the industry now aiming for a 60-day turnaround target. The rapid development of mRNA technology has been key to this acceleration, offering a future of exponential growth at rapid speed and low cost. New delivery systems, such as intranasal and patches, are also being developed. Regulatory authorities have shown flexibility in reviewing protocols and giving clear guidance, and remote monitoring is becoming more prevalent in clinical trial design. Novotech, a leading biotech CRO, has experience in over 100 vaccine trials and has established strong site collaboration with over 800 vaccine trial sites globally.